Logo image of MXCT

MAXCYTE INC (MXCT) Stock Fundamental Analysis

USA - NASDAQ:MXCT - US57777K1060 - Common Stock

1.63 USD
+0.01 (+0.62%)
Last: 10/24/2025, 8:00:01 PM
1.63 USD
0 (0%)
After Hours: 10/24/2025, 8:00:01 PM
Fundamental Rating

3

Overall MXCT gets a fundamental rating of 3 out of 10. We evaluated MXCT against 57 industry peers in the Life Sciences Tools & Services industry. While MXCT has a great health rating, there are worries on its profitability. MXCT is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

MXCT had negative earnings in the past year.
MXCT had a negative operating cash flow in the past year.
MXCT had negative earnings in each of the past 5 years.
In the past 5 years MXCT always reported negative operating cash flow.
MXCT Yearly Net Income VS EBIT VS OCF VS FCFMXCT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M -50M

1.2 Ratios

With a Return On Assets value of -20.37%, MXCT is not doing good in the industry: 63.16% of the companies in the same industry are doing better.
MXCT's Return On Equity of -23.47% is in line compared to the rest of the industry. MXCT outperforms 47.37% of its industry peers.
Industry RankSector Rank
ROA -20.37%
ROE -23.47%
ROIC N/A
ROA(3y)-13.17%
ROA(5y)-13.81%
ROE(3y)-15.17%
ROE(5y)-17.68%
ROIC(3y)N/A
ROIC(5y)N/A
MXCT Yearly ROA, ROE, ROICMXCT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 100

1.3 Margins

MXCT's Gross Margin of 79.79% is amongst the best of the industry. MXCT outperforms 100.00% of its industry peers.
In the last couple of years the Gross Margin of MXCT has declined.
MXCT does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 79.79%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.94%
GM growth 5Y-1.59%
MXCT Yearly Profit, Operating, Gross MarginsMXCT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100

More info and screens

7

2. Health

2.1 Basic Checks

MXCT does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, MXCT has more shares outstanding
Compared to 5 years ago, MXCT has more shares outstanding
MXCT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
MXCT Yearly Shares OutstandingMXCT Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
MXCT Yearly Total Debt VS Total AssetsMXCT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

An Altman-Z score of 2.14 indicates that MXCT is not a great score, but indicates only limited risk for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 2.14, MXCT is in line with its industry, outperforming 50.88% of the companies in the same industry.
There is no outstanding debt for MXCT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 2.14
ROIC/WACCN/A
WACC10.51%
MXCT Yearly LT Debt VS Equity VS FCFMXCT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M 200M 250M

2.3 Liquidity

A Current Ratio of 12.39 indicates that MXCT has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 12.39, MXCT belongs to the top of the industry, outperforming 94.74% of the companies in the same industry.
MXCT has a Quick Ratio of 11.71. This indicates that MXCT is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 11.71, MXCT belongs to the top of the industry, outperforming 94.74% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 12.39
Quick Ratio 11.71
MXCT Yearly Current Assets VS Current LiabilitesMXCT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

4

3. Growth

3.1 Past

The earnings per share for MXCT have decreased strongly by -26.47% in the last year.
The Revenue for MXCT has decreased by -21.31% in the past year. This is quite bad
Measured over the past years, MXCT shows a quite strong growth in Revenue. The Revenue has been growing by 12.31% on average per year.
EPS 1Y (TTM)-26.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-33.33%
Revenue 1Y (TTM)-21.31%
Revenue growth 3Y4.46%
Revenue growth 5Y12.31%
Sales Q2Q%-18.43%

3.2 Future

The Earnings Per Share is expected to decrease by -0.66% on average over the next years.
MXCT is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 28.61% yearly.
EPS Next Y-10.72%
EPS Next 2Y-5.43%
EPS Next 3Y-0.66%
EPS Next 5YN/A
Revenue Next Year-3.89%
Revenue Next 2Y5.04%
Revenue Next 3Y10.54%
Revenue Next 5Y28.61%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
MXCT Yearly Revenue VS EstimatesMXCT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 100M 200M 300M 400M
MXCT Yearly EPS VS EstimatesMXCT Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 -2 -4 -6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for MXCT. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MXCT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MXCT Price Earnings VS Forward Price EarningsMXCT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MXCT Per share dataMXCT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1 1.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-5.43%
EPS Next 3Y-0.66%

More info and screens

0

5. Dividend

5.1 Amount

MXCT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MAXCYTE INC

NASDAQ:MXCT (10/24/2025, 8:00:01 PM)

After market: 1.63 0 (0%)

1.63

+0.01 (+0.62%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)08-06 2025-08-06/amc
Earnings (Next)11-05 2025-11-05/amc
Inst Owners70.62%
Inst Owner Change-0.27%
Ins Owners1.37%
Ins Owner Change4.66%
Market Cap173.77M
Revenue(TTM)35.75M
Net Income(TTM)-44772000
Analysts83.08
Price Target6.47 (296.93%)
Short Float %3.25%
Short Ratio4.21
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-3.61%
Min EPS beat(2)-13.86%
Max EPS beat(2)6.63%
EPS beat(4)3
Avg EPS beat(4)6.24%
Min EPS beat(4)-13.86%
Max EPS beat(4)19.64%
EPS beat(8)6
Avg EPS beat(8)14.2%
EPS beat(12)9
Avg EPS beat(12)14.45%
EPS beat(16)13
Avg EPS beat(16)16.81%
Revenue beat(2)1
Avg Revenue beat(2)-3.6%
Min Revenue beat(2)-12.47%
Max Revenue beat(2)5.28%
Revenue beat(4)3
Avg Revenue beat(4)2.21%
Min Revenue beat(4)-12.47%
Max Revenue beat(4)8.53%
Revenue beat(8)6
Avg Revenue beat(8)11.35%
Revenue beat(12)8
Avg Revenue beat(12)5.7%
Revenue beat(16)12
Avg Revenue beat(16)9.06%
PT rev (1m)0%
PT rev (3m)-9.37%
EPS NQ rev (1m)-3.51%
EPS NQ rev (3m)-31.11%
EPS NY rev (1m)0%
EPS NY rev (3m)-11.4%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-19.98%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-11.67%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.86
P/FCF N/A
P/OCF N/A
P/B 0.91
P/tB 0.93
EV/EBITDA N/A
EPS(TTM)-0.43
EYN/A
EPS(NY)-0.43
Fwd EYN/A
FCF(TTM)-0.36
FCFYN/A
OCF(TTM)-0.34
OCFYN/A
SpS0.34
BVpS1.79
TBVpS1.75
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -20.37%
ROE -23.47%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 79.79%
FCFM N/A
ROA(3y)-13.17%
ROA(5y)-13.81%
ROE(3y)-15.17%
ROE(5y)-17.68%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.94%
GM growth 5Y-1.59%
F-Score2
Asset Turnover0.16
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 41.44%
Cap/Sales 5.01%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 12.39
Quick Ratio 11.71
Altman-Z 2.14
F-Score2
WACC10.51%
ROIC/WACCN/A
Cap/Depr(3y)270.47%
Cap/Depr(5y)255.66%
Cap/Sales(3y)18.33%
Cap/Sales(5y)14.84%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-26.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-33.33%
EPS Next Y-10.72%
EPS Next 2Y-5.43%
EPS Next 3Y-0.66%
EPS Next 5YN/A
Revenue 1Y (TTM)-21.31%
Revenue growth 3Y4.46%
Revenue growth 5Y12.31%
Sales Q2Q%-18.43%
Revenue Next Year-3.89%
Revenue Next 2Y5.04%
Revenue Next 3Y10.54%
Revenue Next 5Y28.61%
EBIT growth 1Y-13.55%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year29.81%
EBIT Next 3Y14.02%
EBIT Next 5YN/A
FCF growth 1Y-11.95%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-38.01%
OCF growth 3YN/A
OCF growth 5YN/A

MAXCYTE INC / MXCT FAQ

What is the fundamental rating for MXCT stock?

ChartMill assigns a fundamental rating of 3 / 10 to MXCT.


What is the valuation status of MAXCYTE INC (MXCT) stock?

ChartMill assigns a valuation rating of 0 / 10 to MAXCYTE INC (MXCT). This can be considered as Overvalued.


How profitable is MAXCYTE INC (MXCT) stock?

MAXCYTE INC (MXCT) has a profitability rating of 1 / 10.


What is the financial health of MAXCYTE INC (MXCT) stock?

The financial health rating of MAXCYTE INC (MXCT) is 7 / 10.